ALD518

From Self-sufficiency
Jump to: navigation, search
ALD518
Monoclonal antibody
Type ?
Source Template:Infobox drug/mab source
Target IL-6
Clinical data
Routes of
administration		 infusion
Legal status
Legal status
  • investigational
Identifiers
ATC code none
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

ALD518 an asialated, humanized monoclonal antibody against interleukin-6.[1] It is an investigational drug for cancer and rheumatoid arthritis due to its anti-inflammatory properties.

The relatively long half life of about 30 days should allow less frequent and subcutaneous injections.[2]

It is made using yeast cells rather than the standard Chinese hamster ovary cells.[2]

Clinical trials

Cancer

A phase I clinical trial showed ALD518 was well tolerated and could reverse fatigue in cancer patients.[3]

A phase II trial for advanced cancer is due to end in Oct 2009.[4] Results due June 2010[5]. Results from 124 non-small cell lung cancer (NSCLC) patients were favourable (eg. 1/10th the weight loss).[1]

It may be trialled in a dual therapy with Tarceva owing to a likely synergy.[6]

Rheumatoid arthritis

The Phase IIa trial for rheumatoid arthritis[7] has completed with promising results leading to a licencing deal allowing phase III trials.[8] The results are to be presented in June 2010 at the European League Against Rheumatism (EULAR) meeting in Rome.[9]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

See also

Stub icon This pharmacology-related article is a stub. You can help ssf by expanding it.
  1. ↑ 1.0 1.1 "Phase 2a study of ALD518 for treatment of non small cell lung cancer (NSCLC) symptoms". June 2010. 
  2. ↑ 2.0 2.1 http://www.xconomy.com/seattle/2008/09/18/alder-sets-stage-for-showdown-with-roche-with-fast-follower-antibody-drug-strategy/
  3. ↑ http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32916 "A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer." 2009
  4. ↑ http://www.boliven.com/clinical_trial/NCT00866970 Phase II: "Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-Related Fatigue and Cachexia"
  5. ↑ http://www.xconomy.com/seattle/2010/05/13/alder-seeks-to-treat-cancer-patients-in-a-radical-way-fighting-inflammation-not-tumors/?single_page=true
  6. ↑ http://www.nature.com/scibx/journal/v3/n35/full/scibx.2010.1056.html Inflaming resistance to Tarceva. 2010
  7. ↑ http://clinicaltrials.gov/ct2/show/NCT00867516
  8. ↑ http://www.smartbrief.com/news/aanp/industryBW-detail.jsp?id=9279E59B-9E2A-4823-9476-17782B175A34 "Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic" 10 Nov 2009
  9. ↑ http://www.xconomy.com/seattle/2010/03/19/innovation-northwest-wrapup-alder-tekmira-acucela-other-emerging-little-biotechs/
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=ALD518&oldid=23845"